Frontiers in Molecular Biosciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2025-04-21 ms5000002977722155 来自北京

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：分子生物
经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。
审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。

8 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2025-04-20 145d9400m83暂无昵称来自北京

太慢了

10 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2024-07-15 ms5000001250467069 来自江西省

偏重的研究方向：心血管
经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？

107 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-10-25 mswert122

审稿周期大概多久？

123 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-06-11 ms4000001314716194

影响因子是多少啊

160 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-03-11 CH常来自北京

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：Cancer
经验分享：今年安全了，刚中了一篇综述

137 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-04 Chiah

审稿速度:4.0 | 投稿命中率:50.0
经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考

181 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-08-19 123170bfm97(暂无昵称)

中科院预警了还能投么？会报销版面费么？

184 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-05-21 peach_adore

mark

213 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261487, encodeId=4a72226148eb2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子生物 经验分享：期刊挺不错的，适合分子机制、交叉学科类研究；原创研究、综述、方法学、假设与理论等都接收。 审稿速度还可以，意见专业，我是substantial和moderate修改各一个，修改后重新提交，我还小小润色了一下，（求严格，建议投稿前还是要进行专业润色）最后被后录用。共计耗时差不多3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722155, createdTime=Mon Apr 21 23:07:35 CST 2025, time=2025-04-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2261271, encodeId=c21f22612e158, content=太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sun Apr 20 19:20:57 CST 2025, time=2025-04-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214974, encodeId=513922149e416, content=偏重的研究方向：心血管 经验分享：7月2日刚提交，生信加实验验证，第二天就Independent Review，这个是好事还是坏事，显示一个REVIEW is going？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9cb8816098, createdName=ms5000001250467069, createdTime=Mon Jul 15 09:28:21 CST 2024, time=2024-07-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1063736, encodeId=74e11063e36b7, content=审稿周期大概多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Oct 25 11:50:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225890, encodeId=82d41225890ba, content=影响因子是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4a655416689, createdName=ms4000001314716194, createdTime=Sat Jun 11 22:25:05 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119003, encodeId=1f3d211900309, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：Cancer 经验分享：今年安全了，刚中了一篇综述, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLq9qicTF5QNWGwDWEGu4UJTFXWabibYowE3lXECcPLCbLiaUuk73vtAZZEZ92AaV4W4d2CicGicXByDJA/132, createdBy=ce9b2265216, createdName=CH常, createdTime=Sat Mar 11 23:51:10 CST 2023, time=2023-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076702, encodeId=9bc810e670206, content=审稿速度:4.0 | 投稿命中率:50.0 经验分享：Initial validation阶段被拒，生信+实验验证我自己中了两篇6、7分的生信根据最近这个杂志发表的论文和我收到的几份这个杂志邀请审稿的生信论文水平。新颖度和工作量应该是绰绰有余，然而在initial阶段被拒，认为不符合杂志出版要求。感觉很迷。以上供参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d1265488636, createdName=Chiah, createdTime=Sat Dec 04 02:41:56 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239681, encodeId=ad19123968114, content=中科院预警了还能投么？会报销版面费么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36a02382367, createdName=123170bfm97(暂无昵称), createdTime=Fri Aug 19 10:23:37 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221463, encodeId=7b6e1221463ef, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:29:32 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085410, encodeId=46a01085410af, content=投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=574f5417698, createdName=鸭嘴兽花, createdTime=Wed Dec 29 12:36:43 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 鸭嘴兽花

投稿近一个月，依旧initial validation.有遇到相同问题的吗，求指点

174 3 举报

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务